These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 15049991

  • 21. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone.
    Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H.
    J Urol; 2004 Aug; 172(2):658-63. PubMed ID: 15247755
    [Abstract] [Full Text] [Related]

  • 22. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.
    Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N, Testosterone Gel Study Group.
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2839-53. PubMed ID: 10946892
    [Abstract] [Full Text] [Related]

  • 23. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.
    Mazer N, Bell D, Wu J, Fischer J, Cosgrove M, Eilers B, BS, RN,.
    J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men.
    Kaufman JM, Miller MG, Garwin JL, Fitzpatrick S, McWhirter C, Brennan JJ.
    J Sex Med; 2011 Jul; 8(7):2079-89. PubMed ID: 21492400
    [Abstract] [Full Text] [Related]

  • 25. Clinical experience using the Androderm testosterone transdermal system in hypogonadal adolescents and young men with beta-thalassemia major.
    De Sanctis V, Vullo C, Urso L, Rigolin F, Cavallini A, Caramelli K, Daugherty C, Mazer N.
    J Pediatr Endocrinol Metab; 1998 Jul; 11 Suppl 3():891-900. PubMed ID: 10091163
    [Abstract] [Full Text] [Related]

  • 26. [Scrotal testosterone patches: a good addition to therapeutic options for hypogonadal men].
    Asscheman H, Gooren LJ.
    Ned Tijdschr Geneeskd; 2000 Apr 29; 144(18):847-50. PubMed ID: 10816775
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men.
    Raynaud JP, Aumonier C, Gualano V, Betea D, Beckers A.
    J Steroid Biochem Mol Biol; 2008 Mar 29; 109(1-2):177-84. PubMed ID: 18325758
    [Abstract] [Full Text] [Related]

  • 28. Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men.
    Behre HM, Heinemann L, Morales A, Pexman-Fieth C.
    Aging Male; 2008 Jun 29; 11(2):101-6. PubMed ID: 18570063
    [Abstract] [Full Text] [Related]

  • 29. Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose.
    Brocks DR, Meikle AW, Boike SC, Mazer NA, Zariffa N, Audet PR, Jorkasky DK.
    J Clin Pharmacol; 1996 Aug 29; 36(8):732-9. PubMed ID: 8877678
    [Abstract] [Full Text] [Related]

  • 30. Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index.
    Dobs A, Norwood P, Potts S, Gould E, Chitra S.
    J Sex Med; 2014 Mar 29; 11(3):857-64. PubMed ID: 24283410
    [Abstract] [Full Text] [Related]

  • 31. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel.
    Marbury T, Hamill E, Bachand R, Sebree T, Smith T.
    Biopharm Drug Dispos; 2003 Apr 29; 24(3):115-20. PubMed ID: 12673669
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men.
    Wang C, Ilani N, Arver S, McLachlan RI, Soulis T, Watkinson A.
    Clin Endocrinol (Oxf); 2011 Dec 29; 75(6):836-43. PubMed ID: 21689131
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. An open-label, phase 2, single centre, randomized, crossover design bioequivalence study of AndroForte 5 testosterone cream and Testogel 1% testosterone gel in hypogonadal men: study LP101.
    Wittert GA, Harrison RW, Buckley MJ, Wlodarczyk J.
    Andrology; 2016 Jan 29; 4(1):41-5. PubMed ID: 26754331
    [Abstract] [Full Text] [Related]

  • 35. Natesto™ , a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men.
    Rogol AD, Tkachenko N, Bryson N.
    Andrology; 2016 Jan 29; 4(1):46-54. PubMed ID: 26695758
    [Abstract] [Full Text] [Related]

  • 36. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study.
    Kaufman JM, Miller MG, Fitzpatrick S, McWhirter C, Brennan JJ.
    J Sex Med; 2012 Apr 29; 9(4):1149-61. PubMed ID: 22321357
    [Abstract] [Full Text] [Related]

  • 37. Testosterone treatment comes of age: new options for hypogonadal men.
    Nieschlag E.
    Clin Endocrinol (Oxf); 2006 Sep 29; 65(3):275-81. PubMed ID: 16918944
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
    Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, Mazer NA.
    Clin Endocrinol (Oxf); 1997 Dec 29; 47(6):727-37. PubMed ID: 9497881
    [Abstract] [Full Text] [Related]

  • 40. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM, Simhan J, Carson CC.
    BJU Int; 2009 May 29; 103(9):1179-83. PubMed ID: 19154450
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.